ArticleAmerican journal of translational research2025
Effects of metformin combined with insulin aspart on gestational weight gain, lipid metabolism, immune function, and delivery outcomes in pregnant women with gestational diabetes.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Insulin plus metformin for gestational diabetes mellitus: impacts on blood glucose, coagulation function, and pregnancy outcomes.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effects of metformin combined with insulin aspart on gestational weight gain, lipid metabolism, immune function, and delivery outcomes in women with gestational diabetes mellitus (GDM).
methodsClinical data from 95 GDM patients were retrospectively analyzed. Patients were divided into two groups: the control group (45 cases) received only insulin aspart, and the study group (50 cases) received a combination of metformin and insulin aspart. Clinical efficacy, blood glucose levels, body weight, lipid metabolism levels [total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low - density lipoprotein cholesterol (LDL-C)], immune function, insulin resistance [fasting insulin (FINS), homeostasis model assessment of β-cell function (HOMA-β), homeostasis model assessment of insulin resistance (HOMA-IR)], inflammatory markers, delivery outcomes, and drug safety were compared between the two groups.
resultsThe study group had a significantly higher total effective rate (96.00%) compared to the control group (80.00%) (P < 0.05). Post-treatment, blood glucose levels decreased significantly in both groups, with lower levels observed in the study group (all P < 0.05). Both groups showed weight gain, but the increase was less in the study group (P < 0.05). Levels of TC, TG, LDL-C, FINS, HOMA-IR, and inflammatory markers decreased significantly in both groups, with greater reductions in the study group (all P < 0.05). HDL-C, immune function markers, and HOMA-β increased, with more significant increases in the study group (all P < 0.05). The incidence of adverse delivery outcomes was significantly lower in the study group (26.00% vs. 62.22%) (P < 0.05), with no significant difference in adverse reaction rates (10.00% vs. 8.89%) (P > 0.05).
conclusionMetformin combined with insulin aspart demonstrates significant therapeutic benefits in treating GDM. It effectively regulates blood glucose and lipid metabolism, controls weight gain, enhances immune function, reduces insulin resistance, suppresses inflammation, and lowers the incidence of adverse delivery outcomes, with good drug safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.